HomeAI · summaries
Storia in 3 fonti
FDA approves Lytenava for wet AMD
The FDA approved Lytenava for the treatment of neovascular age-related macular degeneration, according to a press release from Outlook Therapeutics.The approval of Lytenava is marks the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the United States.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
FDA approves Lytenava for wet AMD
The FDA approved Lytenava for the treatment of neovascular age-related macular degeneration, according to a press release from Outlook Therapeutics.The approval of Lytenava is…
- ·
medpagetoday.com
FDA Approves Branded Bevacizumab for Wet AMD
Approval follows 20 years of off-label use of compounded formulations of the VEGF inhibitor
